IHE vs. XBI: Pharma Stability or Biotech Growth -- Which Healthcare ETF Is the Better Buy?

The iShares U.S. Pharmaceuticals ETF (IHE) is described as offering a higher dividend yield than the State Street SPDR S&P Biotech ETF (XBI). The article also claims IHE has significantly lower historical volatility than XBI. Overall, the piece is positioning IHE as a potentially more stable, income-oriented alternative within biotech/pharma exposure, without indicating any new fundamental or policy change.

Analysis

The iShares U.S. Pharmaceuticals ETF (IHE) is described as offering a higher dividend yield than the State Street SPDR S&P Biotech ETF (XBI). The article also claims IHE has significantly lower historical volatility than XBI. Overall, the piece is positioning IHE as a potentially more stable, income-oriented alternative within biotech/pharma exposure, without indicating any new fundamental or policy change.